| Print
Spero Therapeutics (SPRO)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Address
675 Massachusetts Avenue
14th Floor
Cambridge
MA
USA
02139
Telephone
+1 857 2421547
Forecast key dates
| Name | Key Date |
|---|---|
| Spero Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-11-13T00:00:00 |
| Spero Therapeutics Inc Second Quarter Earnings Conference Call for 2026 | 2026-08-12T16:30:00 |
| Spero Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-08-12T00:00:00 |
| Spero Therapeutics Inc Annual General Meeting for 2026 | 2026-06-12T09:00:00 |
| Spero Therapeutics Inc First Quarter Earnings Results for 2026 | 2026-05-13T00:00:00 |
| Spero Therapeutics Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-03-27T16:30:00 |
| Spero Therapeutics Inc Fourth Quarter Earnings Results for 2025 | 2026-03-27T00:00:00 |
| Spero Therapeutics Inc Annual Report for 2025 | 2026-03-27T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Spero Therapeutics Inc Third Quarter Earnings Results for 2025 | 2025-11-13T00:00:00 |
| Spero Therapeutics Inc Second Quarter Earnings Conference Call for 2025 | 2025-08-12T16:30:00 |
| Spero Therapeutics Inc Second Quarter Earnings Results for 2025 | 2025-08-12T00:00:00 |
| Spero Therapeutics Inc Annual General Meeting for 2025 | 2025-06-12T09:00:00 |
| Spero Therapeutics Inc First Quarter Earnings Results for 2025 | 2025-05-13T00:00:00 |
| Spero Therapeutics Inc Fourth Quarter Earnings Conference Call for 2024 | 2025-03-27T16:30:00 |
| Spero Therapeutics Inc Fourth Quarter Earnings Result for 2024 | 2025-03-27T00:00:00 |
| Spero Therapeutics Inc Annual Report for 2024 | 2025-03-27T00:00:00 |
| TD Cowen 45th Annual Health Care Conference | 2025-03-05T15:10:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.